Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology and Macrophage Checkpoint Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for QPCTL drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | QPCTL Recombinant Enzyme (Human/Mouse) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Native Golgi-catalytic domain folding. |
View QPCTL Products |
| Gene Delivery | QPCTL Promise-ORF / Lentivirus Particles Full-length ORF for establishing stable overexpression or knockout cellular screening models. |
View QPCTL Products |
| Benchmark Ab | Anti-QPCTL Reference Antibody Recombinant positive control for western blot and target quantification. |
View QPCTL Products |
| Validator | QPCTL siRNA Set For specific gene knockdown verification in cell-based pyroglutamate formation assays. |
View QPCTL Products |
| Related Target A | CD47 Primary physiological substrate of QPCTL; pyroglutamate modification is essential for SIRPα binding. |
View CD47 Products |
| Related Target B | SIRPA Macrophage inhibitory receptor that interacts with pGlu-modified CD47 to initiate the "Don't eat me" signal. |
View SIRPA Products |
| Related Target C | QPCT Paralog enzyme (IsoQC vs QC); essential counter-screening target for evaluating small molecule inhibitor selectivity. |
View QPCT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Off-Target Counter-Screening (QPCTL vs QPCT) | Human and Mouse ortholog and paralog proteins available with >95% purity verified by SDS-PAGE and mass spectrometry for rigorous selectivity profiling. |
| Substrate Cyclization & Enzyme Kinetics Evaluation | Recombinant active catalytic domains expressed in mammalian and bacterial systems with sequence-verified active sites to ensure consistent biochemical baseline parameters. |
| Lack of Standardized Cellular Controls | High-titer Lentivirus premade particles for robust cell line construction, preserving intact Golgi localization for phenotypic screening. |
| False Positives in Small Molecule Screens | Sequence-verified siRNA sets included for target specificity verification and genetic phenocopying. |
Live QPCTL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for QPCTL (Glutaminyl-peptide cyclotransferase-like protein / IsoQC) therapeutics is intensifying as the field seeks safer, more effective alternatives to direct CD47 blockade. While first-generation anti-CD47 monoclonal antibodies have been hindered by severe hematological toxicities such as anemia and hemagglutination, QPCTL inhibition represents a novel small-molecule strategy to disrupt the CD47-SIRPα checkpoint upstream. By selectively blocking the N-terminal pyroglutamate (pGlu) maturation of CD47 within the Golgi apparatus, QPCTL inhibitors abrogate SIRPα binding while sparing normal circulating red blood cells from systemic antibody-mediated clearance. Major players are shifting focus toward orally bioavailable small molecule inhibitors designed for combination regimens with tumor-associated antigen (TAA) antibodies, T-cell engagers, and PD-1/PD-L1 checkpoint inhibitors to unleash potent macrophage phagocytosis inside solid and hematological tumor microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Vivoryon Therapeutics, KSQ Therapeutics, Tenaya Therapeutics | Relapsed/Refractory AML, DLBCL, Solid Tumors | Selectivity Assay (Need high-purity QPCTL vs QPCT paralog enzymes to avoid neuro-off-target effects) |
| Targeted Protein Degrader (PROTAC) | Academic Institutions, Emerging Biotech Networks | Immuno-Oncology, Hematological Malignancies | Degradation Kinetics & Cellular Phenotyping (Need high-titer Lentivirus and sequence-verified siRNA controls) |
| Combination Immuno-Therapy | Immune-Onc, Big Pharma Collaborations | Solid Tumors (combined with Trastuzumab/Cetuximab) | Substrate Modification Assay (Need sequence-verified CD47 substrate antigens and recombinant reference antibodies) |